Repligen Corporation (RGEN)
Here's Why Shares in This Hot Healthcare Stock Surged This Week
A far larger peer backs up Repligen's market commentary. Bioprocessing customers are working through inventory, and orders growth is bouncing back.
These Analysts Revise Their Forecasts On Repligen Following Q2 Results
Repligen Corporation RGEN reported in-line earnings for its second quarter on Tuesday.
Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates
Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024.
Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript
Repligen Corporation [RGEN] Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET Company Participants Tony Hunt - CEO Jason Garland - CFO Olivier Loeillot - President & CCO Sondra Newman - IR Conference Call Participants Rachel Vatnsdal - J.P. Morgan Dan Arias - Stifel Jacob Johnson - Stephens Inc. Puneet Souda - Leerink Partners Justin Bowers - Deutsche Bank Matt Larew - William Blair Conor McNamara - RBC Capital Markets Dan Leonard - UBS Paul Knight - KeyBanc Matt Hewitt - Craig-Hallum Capital Group Matt Stanton - Jefferies Tom DeBourcy - Nephron Research Subbu Nambi - Guggenheim Securities Operator Good day, ladies and gentlemen, and welcome to Repligen Corporation's Second Quarter of 2024 Earnings Conference Call.
Repligen Lowers Guidance On China Weakness, Analyst Expects
Tuesday, Repligen Corporation RGEN reported second-quarter sales of $154.1 million, almost in line with the consensus estimate of $154.12 million.
Repligen (RGEN) Q2 Earnings Meet Estimates
Repligen (RGEN) came out with quarterly earnings of $0.33 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.53 per share a year ago.
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Repligen (RGEN) Promotes CCO, Shares Fall on Leadership Change
Repligen (RGEN) appoints Olivier Loeillot as the company's new president and chief executive officer, effective from Sep 1, 2024. Stock falls on the news.
